Avaliação dos casos de osteonecrose dos maxilares associados ao uso drogas antirreabsortivas

##plugins.themes.bootstrap3.article.main##

Kadyna Daiara Batista Lucio
Ana Paula Ferreira Matos Lira
Stwart de Lucena Wanderley
Maria Cristina Tavares de Medeiros Honorato
Angelo Brito Pereira de Melo
Isis Sant’Anna Araújo Rodrigues Costa

Resumo

Objetivo: Avaliar os casos de osteonecrose dos maxilares associados ao uso de drogas antirreabsortivas atendidos no ambulatório de Cirurgia Bucomaxilofacial. Métodos: Estudo retrospectivo, de delineamento transversal, com abordagem quantitativa, de caráter descritivo. Os dados foram extraídos a partir de consultas aos prontuários físico, tabulados em planilhas do Microsoft Excel e analisados no Statistical Package for Social Sciences. Resultados: A amostra contou com 10 indivíduos, com prevalência do sexo feminino (90%), com faixa etária igual ou superior a 60 anos. O alendronato foi a droga mais utilizada (60%), a via oral foi a mais empregada com 90% dos casos e o tempo de exposição à medicação de 4 a 5 anos. O estágio 2 da osteonecrose prevaleceu em 60% dos indivíduos, apresentando-se como principal localização a mandíbula (80%), com abordagem por tratamentos cirúrgicos e não-cirúrgicos. Conclusão: A terapia prolongada associada a condições sistêmicas aumenta o risco do desenvolvimento da doença e tornam-se fatores agravantes no tratamento.

##plugins.themes.bootstrap3.article.details##

Como Citar
LucioK. D. B., LiraA. P. F. M., WanderleyS. de L., HonoratoM. C. T. de M., MeloA. B. P. de, & CostaI. S. A. R. (2025). Avaliação dos casos de osteonecrose dos maxilares associados ao uso drogas antirreabsortivas. Revista Eletrônica Acervo Saúde, 25(6), e20601. https://doi.org/10.25248/reas.e20601.2025
Seção
Artigos Originais

Referências

1. AMIGUES C, et al. Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database. Joint Bone Spine, 2023; 90(6): 105599.

2. AREDE DP, et al. Osteonecrosis of the jaw with the use of bisphosphonates and treatment with laser therapy and magnetotherapy: a concise systematic review. MedNEXT Journal of Medical and Health Sciences, 2023; 4(2).

3. ASSILI Z, et al. A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva®) Related Osteonecrosis of the Jaw: A Retrospective Study. Journal of Clinical Medicine, 2021; 10(11): 2390.

4. BANSAL H. Osteonecrose da mandíbula relacionada a medicamentos: uma atualização. Revista Nacional de Cirurgia Maxilofacial, 2022; 13(1): 5.

5. BEDOGNI A, et al. Italian position paper (SIPMO‐SICMF) on medication‐related osteonecrosis of the jaw (MRONJ). Oral Diseases, 2024.

6. BRZAK BL, et al. Osteonecrose da mandíbula. Revista Odontologia, 2023; 11(1):23.

7. DIAS AA, et al. A Fotobiomodulação como alternativa no tratamento da osteonecrose dos maxilares relacionada à medicamentos: uma revisão da literatura. Revista Científica FACS, 2023; 23(2): 01-09.

8. DIAS KS, et al. Bisphosphonate-associated osteonecrosis of the jaw in oncology patient: case report. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology,2024; 137(6): e247.

9. EGUIA A, et al. Review and update on drugs related to the development of osteonecrosis of the jaw. Medicina oral, patologia oral y cirugia bucal, 2020; 25(1): e71.

10. GIUDICE A, et al. The case of medication-related osteonecrosis of the jaw addressed from a pathogenic point of view. Innovative therapeutic strategies: Focus on the most recent discoveries on oral mesenchymal stem cell-derived exosomes. Pharmaceuticals, 2020; 13(12): 423.

11. GUPTA M, GUPTA N. Bisphosphonate Related Jaw Osteonecrosis. StatPearls Publishing; 2024.

12. HANNA R, et al. A Systematic Review of Laser Photobiomodulation Dosimetry and Treatment Protocols in the Management of Medications-Related Osteonecrosis of the Jaws: A Rationalised Consensus for Future Randomised Controlled Clinical Trials. Pharmaceuticals, 2024; 17(8): 1011.

13. HOCHMULLER M. et al. Diagnóstico, tratamento e prevenção da osteonecrose maxilar relacionada a medicamentos. Revista Brasileira Multidisciplinar, 2021; 24(2):233-247.

14. IZZETTI R, et al. Panoramic Radiography Features of Medication‐Related Osteonecrosis of the Jaws (MRONJ). International Journal of Dentistry, 2023; 2023(1): 5358849.

15. KAWAHARA M, et al. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. International journal of implant dentistry,2021; 7(1): 47.

16. KO YY, et al. The Role of Cone Beam Computed Tomography (CBCT) in the Diagnosis and Clinical Management of Medication-Related Osteonecrosis of the Jaw (MRONJ). Diagnostics, 2024; 14(16): 1700.

17. KUROSHIMA S, et al. Medication‐related osteonecrosis of the jaw: a literature review and update. Genesis, 2022; 60(8-9): 23500.

18. KWOEN M, et al. Association between periodontal disease, tooth extraction, and medication‐related osteonecrosis of the jaw in women receiving bisphosphonates: A national cohort‐based study. Journal of Periodontology, 2023; 94(1): 98-107.

19. LIMONES A, et al. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis. Medicina oral, patologia oral y cirugia bucal, 2020; 25(3): e326.

20. LIU F, et al. Jaw osteoporosis: Challenges to oral health and emerging perspectives of treatment. Biomedicine & Pharmacotherapy, 2024; 177: 116995.

21. MAUCERI R, et al. Oral Squamous Cell Carcinoma Mimicking Medication-Related Osteonecrosis of the Jaws (MRONJ): A Case Series. Oral, 2021; 1(4): 326-331.

22. MELZER RS, et al. A retrospective study of medication-related osteonecrosis of the jaw in multiple myeloma patients. Journal of bone marrow transplantation and cellular therapy, 2023; 4(3): 209-209.

23. MEREY SE, et al. Pentoxifylline and Tocopherol in the Management of Stage III Medication-Related Osteonecrosis of the Jaw: A Case Report. Akdeniz Diş Hekimliği Dergisi, 2023; 2(3):162-167.

24. MIRELLI C, et al. Medication-related osteonecrosis of the jaw in dental practice: A retrospective analysis of data from the Milan cohort. Dentistry Journal, 2022; 10(5): 89.

25. MORAES CM, et al. Osteonecrose dos maxilares associada ao uso dos bisfosfonatos: revisão de literatura. Revista saúde multidisciplinar, 2020; 8(2).

26. MORAIS RPL, et al. IS The use of pentoxifylline and tocopherol effective in the treatment of osteoradionecrosis of the jaws or for the treatment of medication-osteonecrosis of the jaw? an overview. Journal of Stomatology, Oral and Maxillofacial Surgery, 2024;101959.

27. OIZUMI T, et al. Osteonecrosis of the jaw in a patient treated with alendronate and then denosumab: A case of dramatic amelioration by minocycline and then etidronate. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 2025; 37(2): 348-355.

28. RIVAS ANM, DONAIRE, JAR. Tratamiento conservador de osteonecrosis maxilar asociada a medicamentos refractaria mediante el uso de protocolo PENTO: reporte de un caso. Odontoestomatología, 2021: 23(38).

29. RUAN H. et al. Medication-related osteonecrosis of the jaw: a retrospective single center study of recurrence-related factors after surgical treatment. Clinical Oral Investigations, 2024; 28(10): 1-12.

30. RUGGIERO SL, et al. American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws—2022 update. Journal of oral and maxillofacial surgery, 2022 80 (5): 920-943.

31. ŞAHIN O, et al. Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients. Brazilian Journal of Otorhinolaryngology, 2022; 88(4): 613-620.

32. SAKAMOTO Y, et al. Medication-related osteonecrosis of the jaw without osteolysis on computed tomography: a retrospective and observational study. Scientific Reports, 2023; 13(1):12890.

33. SANTOS WB, et al. Osteonecrose dos Maxilares associada ao uso crônico de bisfosfonatos: relato de caso. Revista Eletrônica Acervo Saúde, 2020; 12(2): e2398.

34. SEO DD, BORKE, JL. Medication-Related Osteonecrosis of the Jaw–2024 Update. Oral Health Dental Sci, 2024; 8(1):1-6.

35. SHIN JW, et al. Radiological manifestations and clinical findings of patients with oncologic and osteoporotic medication-related osteonecrosis of the jaw. Scientific reports, 2024; 14(1): 8744.

36. SRIVASTAVA A, et al. Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis. Journal of Immunotherapy and Precision Oncology, 2021; 4(4): 196-207.

37. STRAUB A, et al. Bone concentration of ampicillin/sulbactam: a pilot study in patients with osteonecrosis of the jaw. International Journal of Environmental Research and Public Health, 2022; 19 (22): 14917.

38. VELASKI DP, et al. Etiopatogenia da osteonecrose maxilar relacionada a bisfosfonatos. Biosaúde, 2020; 22(2): 84-96.

39. WAN JT, et al. Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors. Bone research; 2020; 8(1):14.

40. YAROM N, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. Journal of Clinical Oncology, 2019; 37(25): 2270-2290.